Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HRTX Heron Therapeutics	$1.91 +0.5%	$2.02	$1.04 ▼ $3.16	$289.87M	1.18	1.33 million shs	589,813 shs
KOD Kodiak Sciences	$8.84 +7.2%	$4.24	$1.92 ▼ $11.60	$435.30M	2.28	503,708 shs	919,845 shs
MGX Metagenomi	$2.43 -3.2%	$1.75	$1.23 ▼ $4.92	$93.83M	-0.38	997,578 shs	511,279 shs
MRNA Moderna	$34.15 +0.4%	$28.58	$23.15 ▼ $125.68	$13.15B	1.84	9.13 million shs	5.37 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HRTX Heron Therapeutics	-3.06%	-5.00%	-11.63%	-17.39%	-39.68%
KOD Kodiak Sciences	+19.57%	+58.96%	+128.53%	+100.73%	+173.18%
MGX Metagenomi	+5.46%	+17.84%	+62.99%	+44.25%	-45.79%
MRNA Moderna	-1.90%	+5.62%	+26.90%	+24.94%	-71.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HRTX Heron Therapeutics	3.8025 of 5 stars	3.5	0.0	4.2	3.0	1.7	0.6
KOD Kodiak Sciences	2.5305 of 5 stars	1.0	2.0	4.6	2.2	3.3	0.0
MGX Metagenomi	3.2232 of 5 stars	3.5	4.0	0.0	3.3	1.7	0.6
MRNA Moderna	4.2501 of 5 stars	4.0	1.0	4.6	1.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HRTX Heron Therapeutics	3.00	Buy	$5.00	161.78% Upside
KOD Kodiak Sciences	2.00	Hold	$9.00	1.81% Upside
MGX Metagenomi	3.00	Buy	$13.00	434.98% Upside
MRNA Moderna	2.04	Hold	$46.11	35.03% Upside

Current Analyst Ratings Breakdown

Latest MGX, MRNA, HRTX, and KOD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/22/2025	MRNA Moderna	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$26.00 ➝ $25.00
7/13/2025	MRNA Moderna	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight
7/13/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight
7/13/2025	MRNA Moderna	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold ➝ Hold
6/9/2025	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
6/2/2025	MRNA Moderna	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
5/22/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$33.00 ➝ $26.00
5/15/2025	MGX Metagenomi	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
5/14/2025	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00 ➝ $16.00
5/2/2025	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $70.00
5/2/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$45.00 ➝ $40.00

(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HRTX Heron Therapeutics	$144.29M	2.02	N/A	N/A	($0.22) per share	-8.68
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.86 per share	N/A
MGX Metagenomi	$52.29M	1.74	N/A	N/A	$6.28 per share	0.39
MRNA Moderna	$3.14B	4.21	N/A	N/A	$28.33 per share	1.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HRTX Heron Therapeutics	-$13.58M	-$0.06	N/A	N/A	N/A	-5.24%	N/A	-3.43%	8/5/2025 (Estimated)
KOD Kodiak Sciences	-$176.21M	-$3.63	N/A	N/A	N/A	N/A	-115.71%	-54.17%	8/13/2025 (Estimated)
MGX Metagenomi	-$78.06M	-$2.11	N/A	N/A	N/A	-172.21%	-31.21%	-22.21%	8/13/2025 (Estimated)
MRNA Moderna	-$3.56B	-$8.73	N/A	N/A	N/A	-105.67%	-28.69%	-21.94%	8/1/2025 (Estimated)

Latest MGX, MRNA, HRTX, and KOD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	KOD Kodiak Sciences	-$1.01	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	MGX Metagenomi	-$0.62	N/A	N/A	N/A	$7.72 million	N/A
8/5/2025	Q2 2025	HRTX Heron Therapeutics	-$0.01	N/A	N/A	N/A	$38.08 million	N/A
8/1/2025	Q2 2025	MRNA Moderna	-$2.97	N/A	N/A	N/A	$116.26 million	N/A
5/14/2025	Q1 2025	KOD Kodiak Sciences	-$0.89	-$1.09	-$0.20	-$1.09	N/A	N/A
5/13/2025	Q1 2025	MGX Metagenomi	-$0.62	-$0.68	-$0.06	-$0.68	$8.75 million	$4.13 million
5/6/2025	Q1 2025	HRTX Heron Therapeutics	-$0.01	$0.01	+$0.02	$0.01	$37.08 million	$38.90 million
5/1/2025	Q1 2025	MRNA Moderna	-$2.92	-$2.52	+$0.40	-$2.52	$130.35 million	$108.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HRTX Heron Therapeutics	N/A	2.40	1.76
KOD Kodiak Sciences	N/A	4.62	4.62
MGX Metagenomi	N/A	5.85	5.85
MRNA Moderna	N/A	4.22	4.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HRTX Heron Therapeutics	80.01%
KOD Kodiak Sciences	89.06%
MGX Metagenomi	N/A
MRNA Moderna	75.33%

Insider Ownership

Company	Insider Ownership
HRTX Heron Therapeutics	5.86%
KOD Kodiak Sciences	45.90%
MGX Metagenomi	17.80%
MRNA Moderna	11.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HRTX Heron Therapeutics	300	152.56 million	143.62 million	Optionable
KOD Kodiak Sciences	90	52.76 million	28.55 million	Optionable
MGX Metagenomi	236	37.38 million	30.73 million	N/A
MRNA Moderna	5,800	386.74 million	344.20 million	Optionable

MGX, MRNA, HRTX, and KOD Headlines

Recent News About These Companies

EU regulator backs Moderna's updated COVID vaccine

July 25 at 11:41 AM | reuters.com

Moderna (MRNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

July 25 at 11:06 AM | zacks.com

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1

July 25 at 8:45 AM | accessnewswire.comA

Universal Beteiligungs und Servicegesellschaft mbH Boosts Stake in Moderna, Inc. (NASDAQ:MRNA)

July 25 at 4:34 AM | marketbeat.com

Moderna (MRNA) Expected to Announce Earnings on Friday

July 25 at 3:51 AM | marketbeat.com

Moderna (MRNA) Stock Slides as Market Rises: Facts to Know Before You Trade

July 24 at 6:51 PM | zacks.com

Kennedy's mRNA Moves Anger MAHA Allies; Winning Back NIH Grants; Start-Up Games HSAs

July 24 at 4:01 PM | msn.com

After Moderna Pulled Its Shot, Combination Flu/COVID Vaccines Hang in Limbo

July 24 at 5:53 AM | biospace.comB

What's Going On With Moderna Stock Wednesday?

July 23 at 3:14 PM | benzinga.com

Moderna (NASDAQ:MRNA) Given New $25.00 Price Target at Bank of America

July 22 at 1:48 PM | marketbeat.com

Wealthfront Advisers LLC Increases Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

July 21, 2025 | marketbeat.com

Moderna, Inc. (NASDAQ:MRNA) Shares Sold by South Dakota Investment Council

July 20, 2025 | marketbeat.com

Moderna, Inc. (NASDAQ:MRNA) Shares Sold by New York State Common Retirement Fund

July 19, 2025 | marketbeat.com

Here's Why Moderna (MRNA) Fell More Than Broader Market

July 18, 2025 | zacks.com

How IBM and Moderna’s partnership could lead to an explosion in drug development

July 18, 2025 | fastcompany.comF

Investors Buy Large Volume of Call Options on Moderna (NASDAQ:MRNA)

July 18, 2025 | marketbeat.com

Moderna cancels Japan mRNA plant plans amid weak demand

July 18, 2025 | asia.nikkei.com

Moderna scraps plans for messenger RNA manufacturing plant in Japan

July 18, 2025 | msn.com

Moderna, facing uncertain business environment, scraps plan to establish mRNA plant in Japan

July 18, 2025 | fiercepharma.comF

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

July 18, 2025 | zacks.com

Moderna cancels plans to build Japan plant on poor business environment

July 18, 2025 | reuters.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX, MRNA, HRTX, and KOD Company Descriptions

Heron Therapeutics NASDAQ:HRTX

$1.91 +0.01 (+0.53%)

Closing price 04:00 PM Eastern

Extended Trading

$1.91 0.00 (0.00%)

As of 07:40 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Kodiak Sciences NASDAQ:KOD

$8.84 +0.59 (+7.15%)

Closing price 04:00 PM Eastern

Extended Trading

$8.80 -0.04 (-0.41%)

As of 07:55 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Metagenomi NASDAQ:MGX

$2.43 -0.08 (-3.19%)

Closing price 04:00 PM Eastern

Extended Trading

$2.40 -0.03 (-1.23%)

As of 06:13 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Moderna NASDAQ:MRNA

$34.15 +0.14 (+0.41%)

Closing price 04:00 PM Eastern

Extended Trading

$34.15 0.00 (-0.01%)

As of 07:57 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time